Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed metastatic or locally recurrent HNSCC that is considered incurable by local therapies.
Safety Run-in Cohort 1 and Phase 2 Cohorts 1
Should not have had prior systemic therapy administered in the recurrent or metastatic setting.
Eligible primary tumor locations include oropharynx, oral cavity, hypopharynx, and larynx. Nasopharynx is not included.
Safety Run-in Cohort 2 and Phase 2 Cohort 3
Histologically or cytologically confirmed locally advanced/mHNSCC regardless of PD-L1 status with at least 1 and no more than 2 lines of prior systemic anticancer therapy in the locally advanced/metastatic setting.
You may not be if
Active central nervous system (CNS) disease (individuals with asymptomatic and stable, treated CNS lesions who have been off corticosteroids, radiation, or other CNS-directed therapy for at least 4 weeks are not considered active).
History of (noninfectious) pneumonitis that required steroids or current pneumonitis.
Progressive disease within 6 months of completion of curatively intended treatment for locally advanced/mHNSCC.
Safety Run-in Cohort 1, Pre-expansion Safety Run-in Cohort for Magrolimab + Pembrolizumab (if Applicable), and Phase 2 Cohorts 1 and 2
Prior treatment with any of the following:
* Anti-programmed cell death protein 1 or anti-PD-L1 checkpoint inhibitors.
* Anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitors.
